mynth
← DATABASE
02/2022MajorityLBO

Montagu Private Equity & Partners Group take majority stake in HTL Biotechnology

FRANCE Life Sciences / Pharma & Biotech / CDMO EV €1–10bn

Context

This transaction marks the third leveraged buyout for HTL Biotechnology, with Montagu Private Equity entering into exclusive negotiations to acquire a majority stake from Bridgepoint. Partners Group joined Montagu as a co-investor in this operation, while the existing management team remains significantly involved in the capital. The strategic rationale for this LBO is to accelerate HTL,s transformation from a specialized hyaluronic acid producer into a diversified, global biopolymer platform. Under the previous ownership, the company significantly expanded its R&D capabilities, doubled its production capacity with a €50M industrial investment, and established a strong presence in the US and Chinese markets. Key to this new phase of growth is a major partnership with Eirion Therapeutics, positioning HTL as the exclusive manufacturer of a novel botulinum toxin using its proprietary fermentation process. Montagu intends to leverage its healthcare expertise to further the group,s internationalization and portfolio diversification, particularly in high-growth segments like tissue engineering. The acquisition is supported by a significant unitranche financing package, reflecting the strong cash-flow generation and premium positioning of the asset in the pharmaceutical supply chain.

In the past, HTL Biotechnology was acquired by Bridgepoint in 2018 as part of its expansion strategy.

HTL Biotechnology, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of Above 20x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in the late 20th century, HTL is a leading global biotechnology company specializing in the development, production, and purification of pharmaceutical-grade hyaluronic acid and other bio-sourced polymers. Based in Brittany, the company utilizes advanced fermentation and purification processes to supply high-purity ingredients to the global healthcare industry. Its value proposition is centered on technical excellence and the ability to provide customized molecular weights for sensitive medical applications, including dermatology for wrinkle filling, ophthalmology for cataract surgery, and rheumatology for joint treatments. HTL,s strategy focuses on continuous innovation through significant R&D investments and the expansion of its industrial capacities to maintain a leadership position in the high-end biopolymer market. By maintaining a discreet but critical role in the pharmaceutical supply chain, the company ensures that global medical device and pharma manufacturers have access to safe, natural, and highly effective components for life-changing medical treatments.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

Above 20x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2021
[members only]
€50–100M
[members only]
2020
[members only]
€50–100M
[members only]

Other operations with HTL Biotechnology

Other operations with HTL Biotechnology
DateAcquirerTargetCountrySector
10/2018BRIDGEPOINTHTL BIOTECHNOLOGYFRANCECDMO

Other operations with Montagu Private Equity / Partners Group

Other operations with Montagu Private Equity / Partners Group
DateAcquirerTargetCountrySector
05/2023TA ASSOCIATES / MONTAGU PRIVATE EQUITYHARVESTFRANCEFinancial Services / Banking
10/2022PARTNERS GROUPTELEPASSITALYFintech & Payments
02/2022PARTNERS GROUPFOREFRONT DERMATOLOGYUNITED STATESOutpatient Care
01/2022PARTNERS GROUPATNORTHICELANDHosting / Datacenter
11/2021PARTNERS GROUPDIVERSITECHUNITED STATESValves, Pumps & Taps
07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCEImplants & Prosthetics
07/2021PARTNERS GROUPPHARMATHENGREECECDMO
01/2021MONTAGU PRIVATE EQUITYIMV TECHNOLOGIESFRANCER&D Biotech
07/2020PARTNERS GROUPROVENSAPORTUGALSpecialty Chemicals
03/2020TETHYS INVEST / CPPIB (CANADA PENSION PLAN INVESTMENT BOARD) / MONTAGU PRIVATE EQUITYGALILEO GLOBAL EDUCATIONFRANCEEducation Providers

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
03/2022FRESENIUSMABXIENCESPAINCDMO
03/2022FRESENIUSIVENIXUNITED STATESDiagnostic Equipment
01/2022ANJAC BEAUTY & HEALTHAPOLLO HEALTHCARE CORP..CANADACDMO
01/2022PERMIRAKEDRIONITALYCDMO
01/2022PERMIRABIO PRODUCTS LABORATORY (BPL)UNITED KINGDOMCDMO
01/2022ARDIANBIOFARMA GROUPITALYCDMO
12/2021THE CARLYLE GROUP / GTCRRESONETICSUNITED STATESMedical Devices
12/2021WINNCAREPHARMAOUEST INDUSTRIESFRANCEMedical Devices
12/2021PLANMECA GROUPKAVO DENTALGERMANYMedical Devices
12/2021INTEGEROSCORUNITED STATESImplants & Prosthetics

REFERENCES

Valuation range: EV €1–10bn

EBITDA range: €50–100M

EV/EBITDA range: Above 20x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HTL Biotechnology by Montagu Private Equity / Partners Group are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: htl biotechnology

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in HTL Biotechnology, a French company specialised in Pharma & Biotech, by Montagu Private Equity and Partners Group in 2022, structured as a leveraged buyout (LBO). This followed an earlier holding cycle initiated in October 2018, when the company was acquired by Bridgepoint.

How was the acquisition of HTL Biotechnology by Montagu Private Equity valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band and its EV/EBITDA multiple within the Above 20x range. Exact figures are available to members.

What was HTL Biotechnology’s EBITDA at the time of the deal?

At the time of the transaction, HTL Biotechnology’s EBITDA was estimated within the €50–100M bracket (FY 2021). Detailed financial figures are available to members.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.